Stated Preferences in Non-Small-Cell Lung Cancer: A Discrete Choice Experiment

April 2021 in “ Patient Preference and Adherence ”

Isandra Meirelles, Carlos Magliano

Studysummary This study found that Brazilian patients with advanced NSCLC required significant survival gains to accept treatments causing severe tiredness or skin rash, with preferences varying among treatment options.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

Read the full study on dovepress.com →

PubMed
DOI

Discuss this study in the Community →

Similar research 5

Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis in Patients on Palliative Treatment for Advanced Breast Cancer Figshare · 2023
Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis in Patients on Palliative Treatment for Advanced Breast Cancer Figshare · 2023
Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis in Patients on Palliative Treatment for Advanced Breast Cancer Breast Care · 2021
Patient, Oncologist, And Payer Preferences For Adjuvant Endocrine Therapy And CDK4/6 Inhibitor Regimens In Early-Stage Breast Cancer: A Discrete Choice Experiment Patient Preference and Adherence · 2021
Dissecting the Genetic Variations Associated with Response to First-Line Chemotherapy in Patients with Small Cell Lung Cancer: A Retrospective Cohort Study Journal of Thoracic Disease · 2023

Related Community Posts Join

6 / 1000+ results

community Best available SARD right now?

in Treatment 3 upvotes 4 months ago

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

community Trial for TDM-105795 update from research office

16 upvotes 2 years ago

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

community Joining clinical study for Clascoterone (Breezula)

in Research/Science 7 upvotes 1 year ago

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

community Thinking about signing up for the setipiprant clinical trials

5 upvotes 9 years ago

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

community PP405 2a study was a safety study. Some rational explaining.

22 upvotes 1 year ago

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting

in Chat 30 upvotes 5 months ago

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.